We are live on ! Find out more
ARMP icon

Armata Pharmaceuticals
ARMP

20 hedge funds and large institutions have $5.73M invested in Armata Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

9% more capital invested

Capital invested by funds: $5.25M → $5.73M (+$485K)

5% more funds holding

Funds holding: 19 → 20 (+1)

0.02% more ownership

Funds ownership: 3.74% → 3.76% (+0.02%)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
20
Holders Change
+1
Holders Change %
+5.26%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$57.2K
2
Osaic Holdings
Osaic Holdings
Arizona
+$22.1K
3
BlackRock
BlackRock
New York
+$9.54K
4
HGERS
Householder Group Estate & Retirement Specialist
Arizona
+$547
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$366

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$41.1K
2
UBS Group
UBS Group
Switzerland
-$5.06K
3
Morgan Stanley
Morgan Stanley
New York
-$4.31K
4
Bank of America
Bank of America
North Carolina
-$2.36K
5
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
1
Bank of America
North Carolina
$2.67M -$2.36K -586 -0.1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.21M +$57.2K +14,200 +5%
BCM
3
Bridgeway Capital Management
Texas
$480K – – –
Edgewood Management
4
Edgewood Management
Connecticut
$422K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$295K -$41.1K -10,200 -13%
SF
6
Synovus Financial
Georgia
$202K – – –
BlackRock
7
BlackRock
New York
$101K +$9.54K +2,370 +11%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$95K – – –
Northern Trust
9
Northern Trust
Illinois
$82K – – –
SWM
10
SeaCrest Wealth Management
New York
$74K – – –
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$56K – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$23K +$22.1K +5,500 New
UBS Group
13
UBS Group
Switzerland
$8K -$5.06K -1,256 -40%
TRCT
14
Tower Research Capital (TRC)
New York
$4K -$841 -209 -19%
Northwestern Mutual Wealth Management
15
Northwestern Mutual Wealth Management
Wisconsin
$2K – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$1K +$366 +91 +212%
Morgan Stanley
17
Morgan Stanley
New York
– -$4.31K -1,070 -100%
CAPTRUST Financial Advisors
18
CAPTRUST Financial Advisors
North Carolina
– -$2K -408 Closed
Wells Fargo
19
Wells Fargo
California
– -$32 -8 -10%
HGERS
20
Householder Group Estate & Retirement Specialist
Arizona
– +$547 +136 New

ARMP Hedge Fund Activity: Q3 2022 in Review

20 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2022, worth a combined $5.73M — up 9.2% from $5.25M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ARMP positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $57.2K. The largest seller was Renaissance Technologies, cutting an estimated $41.1K.

  • 20 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2022, up from 19 in Q2 2022.
  • Funds reported $5.73M of Armata Pharmaceuticals stock for Q3 2022, up 9.2% quarter-over-quarter.
  • 2 funds opened new Armata Pharmaceuticals positions in Q3 2022 and 1 closed out, a net change of +1 holder.
  • The largest Armata Pharmaceuticals buyer in Q3 2022 was Vanguard Group, an estimated $57.2K added.
  • The largest Armata Pharmaceuticals seller in Q3 2022 was Renaissance Technologies, an estimated $41.1K sold.

Based on aggregated 13F filings for Q3 2022.